174879-28-8 Usage
General Description
FMOC-DL-2-aminobutyric acid is a chemical compound consisting of a 2-aminobutyric acid molecule that is protected by a FMOC (9-fluorenylmethoxycarbonyl) group. FMOC-DL-2-AMINOBUTYRIC ACID is often used in peptide synthesis as a building block for incorporating the 2-aminobutyric acid residue into peptides and proteins. The FMOC group serves as a protecting group, allowing for selective deprotection and subsequent coupling reactions during the synthesis process. The 2-aminobutyric acid moiety in the compound can also confer unique properties to the resulting peptides and proteins, making it a valuable tool in chemical biology, drug discovery, and protein engineering research.
Check Digit Verification of cas no
The CAS Registry Mumber 174879-28-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,4,8,7 and 9 respectively; the second part has 2 digits, 2 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 174879-28:
(8*1)+(7*7)+(6*4)+(5*8)+(4*7)+(3*9)+(2*2)+(1*8)=188
188 % 10 = 8
So 174879-28-8 is a valid CAS Registry Number.
InChI:InChI=1/C19H19NO4/c1-2-17(18(21)22)20-19(23)24-11-16-14-9-5-3-7-12(14)13-8-4-6-10-15(13)16/h3-10,16-17H,2,11H2,1H3,(H,20,23)(H,21,22)/p-1/t17-/m1/s1
174879-28-8Relevant articles and documents
Solid-phase synthesis of unnatural α-amino acid derivatives using a resin-bound glycine cation equivalent
O'Donnell, Martin J.,Delgado, Francisca,Drew, Mark D.,Pottorf, Richard S.,Zhou, Changyou,Scott, William L.
, p. 5831 - 5835 (1999)
Unnatural amino acids were synthesized on solid-phase by reaction of a resin-bound Schiff base with organoboranes. This novel use of a resin-bound glycine cation equivalent allows for the preparation of a variety of amino acid structural types not readily available by the complementary anionic equivalent.
Fibrinogen receptor antagonist and pharmaceutical compositions comprising the same
-
, (2008/06/13)
Compounds of the following general formula (I) and pharmaceutically acceptable salts thereof.
